![A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7dd7d4cd-2264-4c31-bc80-529dc65838cb/bjh15232-fig-0003-m.jpg)
A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library
![Mechanism of action of obinutuzumab. Notes: (A) Modification of the... | Download Scientific Diagram Mechanism of action of obinutuzumab. Notes: (A) Modification of the... | Download Scientific Diagram](https://www.researchgate.net/publication/312923059/figure/fig1/AS:454967405355008@1485484090067/Mechanism-of-action-of-obinutuzumab-Notes-A-Modification-of-the-glycan-tree-structure.png)
Mechanism of action of obinutuzumab. Notes: (A) Modification of the... | Download Scientific Diagram
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
![A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/896c79c3-5a73-460f-bca5-f6b896e66f88/bjh15232-fig-0002-m.jpg)
A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library
![An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma - Clinical Lymphoma, Myeloma and Leukemia An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/561a2f15-32b5-4269-aa6c-4c4c87f48070/gr1_lrg.jpg)
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma - Clinical Lymphoma, Myeloma and Leukemia
![A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cb3ac6d5-3a3a-43b7-a056-5806f43d053a/bjh15232-fig-0001-m.jpg)
A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library
![Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram](https://www.researchgate.net/profile/Narges_Seyfizadeh/publication/282659489/figure/fig1/AS:576488051560448@1514456870251/Rituximab-mechanisms-of-action-the-three-major-independent-mechanisms-are-1-antibody_Q640.jpg)
Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g002.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology
![PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/33f339e9d609e1fa7d39a952cafd3e938b2119d3/3-Table2-1.png)
PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar
![Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. - Abstract - Europe PMC Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5994406/bin/fonc-08-00163-g004.jpg)
Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. - Abstract - Europe PMC
![Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions | Research To Practice Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/4/1/Slide03.jpg)
Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions | Research To Practice
![Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL | Research To Practice Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCHEM2013/2/2/Slide03.jpg)
Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL | Research To Practice
![Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways - ScienceDirect Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004221000572-fx1.jpg)